Jeff Dao | Operating Officer and Business Development Officer
HighTide Therapeutics

Jeff Dao, Operating Officer and Business Development Officer, HighTide Therapeutics

Jeff has over three decades of experience in the high tech and life science industries. His focus has been the commercialization of novel technology and innovations spanning the fields of pattern recognition/artificial intelligence, enterprise applications, data analytics, clinical diagnostics and therapeutics.  Mr. Dao’s experience covers a broad spectrum of companies, including one of the first spin-offs of SRI International (aka Stanford Research Institute), Oracle and Nokia.  He has broad and deep operational experience in product management, marketing, commercialization, strategic alliances, corporate development, and mergers and acquisitions.  As head of marketing and sales of CIC, Mr. Dao helped the company complete a successful IPO on NASDAQ.  He has also been involved in the development of in vitro diagnostics for early detection of lung cancer and novel therapies for treating solid tumor cancers.  Mr. Dao’s previous experience includes Senior Director Business Development, Oracle Corporation; Vice President Business Development, Nokia Inc.; Senior Vice President, Genyous Life Sciences; President & Co-CEO, Omnitura Therapeutics; and Senior Vice President Marketing and Business Development, Kairoi Health.  Mr. Dao studied Engineering Physics at the University of California, Berkeley and also participated in Stanford University’s Graduate School of Business Executive Education program.

Appearances:



World Orphan Drug Congress USA 2019 - Day 2 @ 12:45

Pitch 23: HTD1801: a novel multifunctional oral drug candidate for primary sclerosing cholangitis (PSC)

last published: 24/Mar/19 01:45 GMT

back to speakers